Zhuhai Trinomab Biopharmaceutical Co., Ltd. (referred to as "Trinomab"), founded in 2015, is an innovation-driven biopharmaceutical company committed to developing blood product alternatives for global markets.
Leveraging its proprietary "HitmAb? High-Throughput Fully Human Monoclonal Antibody Development Platform" and other technological advantages, the company continuously advance the development of safer and more effective fully human antibody therapies. Its pipeline includes multiple promising antibody drug candidates targeting therapeutic areas such as infectious diseases and pain-related disorders. Among these, the first-in-class Siltartoxatug Injection has been approved for market launch. Siltartoxatug Injection is China’s first domestically developed anti-infective biologic drug designated as a Breakthrough Therapy by the CDE. Its Phase III clinical trial results were featured in live presentations at both the 2024 American College of Emergency Physicians (ACEP) Annual Meeting and the 18th European Emergency Medicine Congress (EUSEM) in 2024, bringing disruptive changes to global tetanus prophylaxis regimens. Another core product, TNM001 (a monoclonal antibody targeting respiratory syncytial virus, RSV), is currently undergoing Phase III clinical trials. It holds the potential to become the world's third and China's first long-acting monoclonal antibody for RSV prevention, applicable to both healthy and high-risk infants.
Guided by our philosophy of "Creating Clinical Value," the company pursues differentiated innovation and competitive strategies.We are committed to the development,manufacturing, and commercialization of fully human monoclonal antibody drugs, as well as potential alternatives to global specialty blood products, addressing critical clinical needs to enhance patient benefits.
